[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Ogura
Michinori
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018390:Gene Targeting; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007211:Indoles; D008224:Lymphoma, Follicular / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D009588:Nitrogen Mustard Compounds; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011684:Purine Nucleosides; D011744:Pyrimidinones; D012306:Risk; D000069283:Rituximab; D016879:Salvage Therapy; D020123:Sirolimus / Q000031:analogs & derivatives; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007211:Indoles; D009588:Nitrogen Mustard Compounds; D011684:Purine Nucleosides; D011744:Pyrimidinones; C113101:forodesine; D000069283:Rituximab; D014750:Vincristine; C401859:temsirolimus; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; C504878:enzastaurin; D011241:Prednisone; D020123:Sirolimus